诱导多能干细胞（iPSC）来源的视网膜色素上皮（RPE）在视网膜变性中的应用：最新进展和未来展望。
iPSC-RPE in Retinal Degeneration: Recent Advancements and Future Perspectives.
机构信息
Research Center, Kobe City Eye Hospital, Kobe 6500-047, Japan.
Department of Ophthalmology, Kobe City Eye Hospital, Kobe 6500-047, Japan.
出版信息
Cold Spring Harb Perspect Med. 2023 Aug 1;13(8):a041308. doi: 10.1101/cshperspect.a041308.
Regenerative medicine is a great hope for patients suffering from diseases for which no effective treatment is available. With the creation of induced pluripotent stem cells (iPSCs) in 2006, research and development has accelerated expeditiously, reaching a practical stage worldwide. The iPSC-regenerative medicine in ophthalmology is one of the pioneers, which has kicked off clinical application ahead of other fields owing to its advantages. The clinical safety issues of iPSC-derived retinal pigment epithelial (iPSC-RPE) transplantation for exudative age-related macular degeneration have been addressed to a certain extent. Preparations are being made for the next clinical study based on the improvement of its therapeutic effects and expansion of indications globally. Steady progress toward the practical applications of regenerative medicine for the treatment of retinal disorders is expected in the future while strengthening global cooperation amid various research areas, clinical fields, and regulations.
再生医学是为那些患有尚无有效治疗方法的疾病的患者带来了巨大的希望。2006 年诱导多能干细胞（iPSC）的诞生，加速了研究和开发的步伐，在全球范围内达到了实用阶段。iPSC 再生医学在眼科是先驱之一，由于其优势，已经领先于其他领域开始临床应用。在一定程度上解决了 iPSC 衍生的视网膜色素上皮（iPSC-RPE）移植治疗渗出性年龄相关性黄斑变性的临床安全性问题。正在根据其治疗效果的提高和全球适应证的扩大，为下一次临床研究做准备。未来，在加强各个研究领域、临床领域和监管领域的全球合作的同时，预计治疗视网膜疾病的再生医学的实际应用将取得稳步进展。
Zotero 插件